Stem Cell Legality — the article + the world, ranked

A fuller editorial guide to stem cell legality is coming soon. For now, the ranking below compares every country we have assessed on it — open a country's report for the cited detail behind its score.

The country comparison

Which countries are best for stem cell legality

The destinations ranked high→low under this lens — each with the reasoning behind its score, the cited evidence one click down, and its full report. The verdict is free; the report is the depth.

19 / 19 Countries ranked

Researched and assessed by the Epidaurus editorial pipeline against our published scale. A country below the rule is not yet assessed enough — never ranked last.

1 Singapore SG 5.0/5 Good Singapore has established a comprehensive, purpose-built legal framework for stem cell regulation through the Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021, featuring a clear risk-based cla... Full report
The evidence behind this score 5 cited points
- Dedicated CTGTP legislation (Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021) with tiered risk classification separate from general pharmaceutical law, making Singapore one of the first Asian countries with stem-cell-specific regulatory architecture
- Two fully approved CAR-T products (Kymriah March 2021, Yescarta March 2023) with established treatment centers and government subsidies from August 2024, demonstrating full institutional integration
- Criminal enforcement framework: unauthorized supply is a criminal offence; misleading advertising carries fines up to S$20,000 and 12 months imprisonment; no documented proliferation of unregulated stem cell clinics
- Robust patient protections: informed consent mandated under Montgomery standard; foreign patients have equal legal standing in courts, SMC complaints, and Healthcare Mediation Scheme
- Framework explicitly aligned with FDA, EMA, MHRA, TGA, and ISSCR standards; abridged registration pathway recognizes prior FDA/EMA approvals; ACTRIS provides GMP manufacturing infrastructure supporting clinical trials and approved services
Read the full Singapore report →
2 Germany DE 4.5/5 Good Germany operates one of Europe's most comprehensive and institutionally rigorous stem cell regulatory frameworks, with dedicated legislation (Medicines Act, Embryo Protection Act, Stem Cell Act, Tissue Act), a special... Full report
The evidence behind this score 5 cited points
- Medicines Act (AMG) with Sections 4b/21a specifically governing ATMPs and stem cell preparations; additional Stem Cell Act (2002/2008), Embryo Protection Act (1990), and Tissue Act (2007) create a multi-layered statutory framework.
- Multiple approved products commercially available: CAR-T therapies Kymriah and Yescarta (both August 2018), Tecartus (December 2020), and Strimvelis (May 2016, first EU-approved ex-vivo haematopoietic stem cell gene therapy), available at >15 certified German university hospitals.
- X-Cell Center in Cologne/Düsseldorf shut down by PEI in April 2011 following pediatric deaths and brain injury; however, clinic operated 2007-2011 treating thousands of foreign patients before enforcement action, demonstrating enforcement lag.
- Patientenrechtegesetz (2013) mandates informed consent and establishes civil liability equally for all patients including foreigners; however, practical barriers (language, geographic distance, litigation costs) limit accessibility of legal recourse for foreign patients.
- June 2024 National Strategy for Gene and Cell Therapies with €44 million federal funding (2023-2026) signals evidence-based regulatory modernization and commitment to balancing access with safety oversight.
Read the full Germany report →
3 Japan JP 4.0/5 Good Japan has a comprehensive, well-resourced regulatory framework with dedicated stem cell legislation (ASRM and PMD Act), a three-tier risk classification system, and 21 approved regenerative medical products as of 2026... Full report
The evidence behind this score 6 cited points
- Dedicated legislation: ASRM (2014) and PMD Act (2014) with three-tier risk classification for cell therapies (Class I: iPSC/ESC; Class II: somatic stem cells; Class III: low-risk somatic cells)
- 21 approved regenerative medical products as of 2026, including world-first allogeneic iPSC-derived therapies (Amchepry for Parkinson's—March 2026; RiHEART for heart failure—February 2026)
- Documented enforcement: Criminal arrests for unauthorized stem cell administration in 2017 (umbilical cord blood) and 2020 (unauthorized adipose culturing); 2024 ASRM amendment adds on-site inspection authority effective May 2025
- Advertising restrictions: PMD Act prohibits unapproved regenerative medicine marketing with criminal penalties (up to 2 years imprisonment or 2M yen fine; 4.5% sales revenue surcharge)
- Structural 'therapeutic haven' gap: ASRM registration does not require proof of efficacy; legal registration may be misinterpreted as clinical endorsement despite lack of evidence; adverse event reporting anomalously low (single-digit per 100,000 administrations compared to benchmarks)
- Foreign patient protections adequate in law but practically difficult: Foreign patients eligible for same treatments and legal standing in malpractice claims, but pursuing litigation from abroad is expensive, time-consuming, and no special protections exist
Read the full Japan report →
4 Spain ES 4.0/5 Good Spain operates a comprehensive, EU-aligned stem cell regulatory framework through AEMPS with multiple approved products (6 CAR-T therapies plus academic ATMPs) and robust legislation (EU Regulation 1394/2007, Royal De... Full report
The evidence behind this score 5 cited points
- Spain implements EU Regulation 1394/2007 and Royal Decree 477/2014, with AEMPS as primary regulatory authority overseeing stem cell products classified as Advanced Therapy Medicinal Products (ATMPs)
- Multiple stem cell products approved: 6 EMA-authorized CAR-T therapies (Yescarta, Kymriah, Tecartus, Abecma, Carvykti, Breyanzi) plus AEMPS-authorized academic ATMPs (ARI-0001, ARI0002h) available in Spain's National Health System
- Hospital exemption pathway under Royal Decree 477/2014 requires clinical efficacy data submission and GMP inspection before authorization—recognized as Europe's most rigorous standard
- Enforcement gap documented: Immucura clinic received AEMPS reports and Junta de Andalucía fines in 2019 and 2022 for unauthorized dendritic cell therapy, yet continued operating and treating 1,000+ patients across six European countries through 2024
- Medical tourists face significant barriers: mandatory informed consent under Law 41/2002, but foreign patients encounter jurisdictional complexity, language barriers, and difficult cross-border malpractice claims with no specialized complaints mechanism for non-EU visitors
Read the full Spain report →
5 United Kingdom GB 4.0/5 Good The UK has a strong regulatory framework for stem cell treatments governed by the Human Medicines Regulations 2012, with multiple expert regulatory bodies (MHRA, HFEA, HTA, CQC) demonstrating clear authority and resou... Full report
The evidence behind this score 5 cited points
- 19 ATMP approvals as of October 2024, including Casgevy (first global CRISPR/Cas9 therapy approved November 2023 ahead of FDA and EMA)
- Comprehensive multi-law regulatory framework: Human Medicines Regulations 2012, Human Fertilisation and Embryology Act 1990, Human Tissue Act 2004, with expert regulatory bodies MHRA, HFEA, HTA, CQC
- Strong clinical trial infrastructure with 175 ongoing ATMP trials and average 49-day MHRA review vs 90-day statutory deadline
- Well-documented enforcement gap: 79% of 24 analyzed commercial stem cell clinics displayed ethically problematic marketing with zero documented regulatory enforcement actions
- Regulatory bodies 'appear to have no position on the non-homologous use of unproven stem cell therapies' despite clear legal authority; jurisdictional ambiguity exists between HFEA and HTA
Read the full United Kingdom report →
6 Israel IL 4.0/5 Good Israel maintains a strong regulatory framework with clear MOH authority, multiple approved stem cell products (hematopoietic stem cell transplantation, CAR-T therapies, OpRegen trials), and specialist committees provi... Full report
The evidence behind this score 5 cited points
- Hematopoietic stem cell transplantation fully approved and reimbursed at designated national centres; CAR-T therapies in national health basket with in-house programs at Sheba, Ichilov, and Hadassah [CAR-T Cell Therapy in Israel - Israeli Hospitals Ltd. - 2024]
- Specialist Central Committee for Clinical Trials with Products Originating from Cells or Tissues provides domain-expert oversight separate from generalist pharmaceutical review [Committees to Approve Clinical Trials in Humans - Israel Academy of Sciences and Humanities - 2024]
- Mandatory MyTrial clinical trial registration system in place since 2016; 19 advanced therapy trials registered by end of 2022, demonstrating active oversight infrastructure [Trends in Israeli Clinical Trials Registration - PMC/NCBI - 2024]
- Patient Rights Act (1996) mandates informed consent and applies to all patients including foreign patients; JCI-accredited hospitals maintain dedicated international patient services [PATIENT'S RIGHTS ACT, 1996 - HaMoked - 1996]
- No documented pattern of unregulated commercial stem cell clinics; Israel not listed as prominent stem cell tourism destination exploiting regulatory absence [International Stem Cell Tourism: A Critical Literature Review - PMC/Oxford Academic - 2022]
Read the full Israel report →
7 South Korea KR 4.0/5 Good South Korea has established a sophisticated regulatory framework through dedicated stem cell legislation (ARMAB Act 2019), approving 15 cell therapies and 3 gene therapies with active enforcement and comprehensive pat... Full report
The evidence behind this score 4 cited points
- South Korea has approved 15 cell therapies and 3 gene therapies as of 2023, achieving the second-highest number of first regenerative medicine approvals globally, including Cartistem® (2012), the first cord blood-derived regenerative medicine approved anywhere in the world
- Dedicated ARMAB legislation (enacted August 2019, implemented August 2020) with amended expanded access provisions effective February 21, 2025, coupled with risk-based classification system for clinical research and mandatory 5-year follow-up for stem cell therapies
- Well-resourced regulatory authority (MFDS) with demonstrated enforcement capacity through multiple oversight layers (MOHW, MFDS, municipal governments) with documented on-site inspections and explicit penalty provisions
- Ambiguous legal status for foreign medical tourists: the February 2025 expanded access pathway is primarily designed for Korean citizens, definition of 'intractable disease' remains unclear, and cross-border legal recourse presents documented challenges despite mandatory informed consent and liability frameworks
Read the full South Korea report →
8 United Arab Emirates AE 3.5/5 Moderate The UAE has a structured regulatory framework with federal and emirate-level authorities, approved stem cell products (HSCT, CAR-T, Casgevy), clear distinctions between autologous and allogeneic therapies, and non-dis... Full report
The evidence behind this score 5 cited points
- Federal Decree-Law No. 38/2024 (effective Jan 2025) explicitly brings biobanks and biological products under pharmaceutical regulation; Cabinet Decision No. 6/2020 governs stem cell storage and clinical application
- Multiple approved products including HSCT (autologous/allogeneic), domestically manufactured CAR-T cells (26 treatments with 80% survival rates as of 2023), and CRISPR-based Casgevy for blood disorders
- Documented enforcement gap: secondary sources confirm rogue clinics continue to offer poorly substantiated treatments with limited regulatory interference; no publicly documented clinic closures, warning letters, or prosecutions for unlicensed stem cell treatments identified (2023-2026)
- ADSCC achieved FACT-JACIE accreditation (May 2024) and JCI Gold Seal (May 2024), providing internationally verified institutional anchor; regulatory framework incorporates ISSCR Guidelines and FDA/EMA reference-based approval model
- Medical Liability Law No. 4/2016 applies non-discriminatorily to all patients regardless of nationality; DHA 2020 standards codify minimally manipulated vs. cultured cell distinction; regulatory trajectory shows 2024-2025 modernization
Read the full United Arab Emirates report →
9 Brazil BR 3.5/5 Moderate Brazil has established a comprehensive regulatory framework (RDC 505/506/836, Law 14.874/2024) with clear ANVISA authority, tiered risk classification, and multiple approved products (HPC, CAR-T, gene therapies), posi... Full report
The evidence behind this score 5 cited points
- Comprehensive ATMP regulatory suite (RDC 505/506/836) with risk-tiered classification and dual ethics oversight (CEP/CONEP), plus modernizing Law 14.874/2024 and Decree 12.651/2025, demonstrating sophisticated framework architecture.
- Seven approved stem cell/advanced therapy products including four CAR-T therapies and two gene therapies, with conditional approval pathway including mandatory long-term post-market surveillance.
- Single major documented enforcement action (Resolução RE 3.402/2024 against R-Crio Criogenia S/A, September 2024) with public safety alert, but report notes ANVISA 'lacks the inspection capacity to monitor every facility' and unauthorized clinics continue operating.
- Lack of stem-cell-specific informed consent requirements for commercial settings and effectively unavailable cross-border legal recourse for foreign patients exposed to unauthorized treatments.
- Framework undergoing active reform with Law 14.874/2024 (enacted May 2024) and Decree 12.651/2025 (October 2025), indicating evolution from partial toward mature regulation rather than stable strong framework.
Read the full Brazil report →
10 Colombia CO 3.5/5 Moderate Colombia operates a bifurcated regulatory system: hematopoietic stem cell transplants and tissue banking are well-regulated by INVIMA under Decreto 2493/2004, but culture-expanded mesenchymal stem cell therapies—the d... Full report
The evidence behind this score 5 cited points
- INVIMA has officially acknowledged that advanced cell therapies do not fit into Colombia's three existing regulatory categories (drugs, anatomical components, medical devices), creating a structural legal vacuum for commercial MSC treatments.
- Enforcement against commercial stem cell clinics is documented as 'little to no'; no warning letters, fines, or clinic closures targeting unauthorized providers have been identified in the public record.
- Foreign patients receive limited legal protection—Colombia's healthcare system is reserved for citizens, malpractice claims are difficult to pursue cross-border, and international health insurance typically does not cover complications from experimental procedures.
- Recent legislative activity shows government commitment to reform: Ley 2253/2022 created a hematopoietic progenitor cell donor registry, Ley 2287/2023 established a national biobanks system, and an advanced therapies bill was under active development as of 2024–2025.
- The regulatory framework is undergoing active modernization with government investment in GMP manufacturing infrastructure (Sala Blanca, COP $35.5 billion) and INVIMA's director initiating regional regulatory harmonization discussions, indicating a trajectory toward formalized stem cell therapy governance.
Read the full Colombia report →
11 Malaysia MY 3.5/5 Moderate Malaysia maintains a coherent multi-agency regulatory framework (NPRA/MOH/MMC) with clear authority over stem cell products through the Sale of Drugs Act 1952 and CDCRs, and has approved two stem cell therapies: hemat... Full report
The evidence behind this score 5 cited points
- Two-tier (Class I/II) CGTP classification with mandatory registration phased in January 2021 (Class I) and January 2025 (Class II), demonstrating proportionate regulation of minimally versus substantially manipulated products
- HSCT fully approved across 13 NSCERT-accredited centers with established registry infrastructure; Zolgensma (Novartis gene therapy) approved via 120-day priority review pathway in February 2024
- Approximately 30 private clinics identified offering unapproved mesenchymal stem cell therapies without NMRR registration; no documented clinic shutdowns or criminal prosecutions for unlicensed stem cell therapy identified in 2023-2025 literature
- NMRR public trial verification platform and mandatory informed consent for registered trials and NPRA products, but no dedicated medical tourism legislation; foreign patients rely on general tort law for malpractice recourse
- CGTP 2nd Edition (September 2025) explicitly aligns manufacturing and registration standards with WHO, ICH, FDA, and EMA benchmarks, indicating active international alignment trajectory
Read the full Malaysia report →
12 Poland PL 3.5/5 Moderate Poland has a well-developed EU ATMP-aligned regulatory framework with multiple approved products (hematopoietic transplants, CAR-T therapies) and legitimate clinical infrastructure. However, the framework experienced ... Full report
The evidence behind this score 5 cited points
- Poland implements EU Regulation (EC) No 1394/2007 (ATMP) with national Article 38a implementation, providing stem-cell-specific regulatory framework
- Multiple approved products available: hematopoietic stem cell transplantation as reimbursed standard of care; six EMA-authorized CAR-T products; PolTREG Treg therapy in Phase II trials with positive EMA pediatric opinion
- Documented major abuse: 1,868 patients received unproven Wharton's jelly MSC treatments for 95+ conditions (2011-2022) with GIF mandate explicitly excluding clinical oversight
- 2018-2023 legislative reform sequence (hospital-only restriction, evidence standards, civil liability insurance, 2023 patient-charging prohibition) responded to exploitation but came through legislation rather than proactive enforcement
- Patient protections now comprehensive (mandatory informed consent, civil liability insurance since 2021, Bioethics Committee approval), but Bioethics Committee specialist capacity concerns and law-practice gap persist
Read the full Poland report →
13 United States US 3.5/5 Moderate The United States maintains a comprehensive and well-structured regulatory framework (21 CFR 1271) with clear FDA authority, multiple approved stem cell therapies, and explicit tiered pathways distinguishing risk leve... Full report
The evidence behind this score 5 cited points
- Comprehensive statutory framework: 21 CFR 1271 (established 2005, revised 2019) with risk-based tiering distinguishing minimally vs. more-than-minimally-manipulated products; FDA approved multiple stem cell therapies including Ryoncil (MSC therapy, December 2024), Casgevy, Lyfgenia for sickle cell disease, and Omisirge for aplastic anemia
- Enforcement failure: Approximately 2,700 clinics selling unapproved treatments as of 2021 despite clear regulatory authority; FDA grace period (2017-2021) paradoxically expanded the illegal market rather than reducing it; FDA issued 400+ warning letters since 2018 with limited compliance effect
- Documented patient harm and underreporting: 360+ reported injuries from stem cell treatments documented between 2004-2020, with severe underreporting to FDA (only 5 of 360 cases in FDA database); documented cases include blindness, infections, and tumors from unapproved treatments
- Regulatory ambiguity from state-federal conflict: Florida, Nevada, and Utah passed laws allowing stem cell therapies not approved by FDA, directly conflicting with federal law; it is unclear how or if FDA will enforce against treatments in these states
- Limited legal protections for medical tourists: Cross-border malpractice claims are particularly challenging; medical tourists face documented risks from 2,700+ unregulated clinics with limited legal recourse and high out-of-pocket costs ($2,000-$25,000) with no insurance coverage
Read the full United States report →
14 Turkey TR 3.0/5 Moderate Turkey's regulatory framework is partial and evolving. While regulatory authorities exist and HSCT (the only approved stem cell treatment) is governed by a functioning national registry and clear indications list, a m... Full report
The evidence behind this score 5 cited points
- Only HSCT for hematologic indications is legally approved under 2018 Ministry of Health Circular; all other stem cell therapies (mesenchymal, umbilical cord-derived) are not authorized for routine clinical use yet dozens of clinics openly market them [Does Turkey Have Stem Cell Therapy in 2025? - Alt Treatment - August 2025]
- No documented enforcement actions, clinic closures, or prosecutions targeting non-HSCT stem cell clinics despite law explicitly prohibiting presentation of clinical research as treatment [Navigating Turkey's Landscape of Stem Cell Therapy - Medical Tourism Magazine - 2024]
- September 2025 Regulation on Products Derived from Human Tissues and Cells represents comprehensive regulatory modernization with tiered licensing, mandatory audits, traceability requirements, and criminal penalties, but enforcement history suggests lag between legislative publication and practical implementation [New Regulation on Products Derived From Human Tissues and Cells - Mondaq/Turkey - 2025]
- HSCT infrastructure demonstrates regulatory capacity: TÜRKKÖK (Turkish Stem Cell Coordination Center) operates as national bone marrow bank with JACIE accreditation and integration with international donor registries [Impact of an Established National Donor Registry - ScienceDirect/BBMT - 2019]
- Foreign patients have equal malpractice standing to citizens by law, but practical protections are undermined by language barriers, geographic distance, enforcement vacuum for unauthorized treatments, and strict filing deadlines [Foreign Patients' Guide to Medical Malpractice in Turkey - Kaymaz Law - 2025]
Read the full Turkey report →
15 Hungary HU 3.0/5 Moderate Hungary has a regulatory foundation through EU ATMP Regulation and general pharmaceutical law, with clear regulatory authority (NNGYK) and one well-established approved therapy (HSCT). However, it lacks dedicated stem... Full report
The evidence behind this score 5 cited points
- No dedicated stem cell or regenerative medicine legislation; Hungary relies on Act CLIV of 1997 on Healthcare and Act XCV of 2005 on Medicinal Products, plus directly applicable EU Regulation (EC) No 1394/2007
- HSCT firmly established as approved therapy (2,500+ procedures at Szent László Hospital since 1993), but no other domestically developed stem cell products approved; EMA-approved CAR-T therapies not routinely reimbursed
- Only one enforcement action documented in 2009 against unlicensed embryonic stem cell operation; no prominent enforcement actions 2020–2026 despite multiple clinics actively marketing experimental stem cell therapies
- Informed consent and general malpractice liability frameworks exist under Act CLIV of 1997, but no stem-cell-specific patient protections; legal recourse for foreign patients is practically challenging
- Hospital exemption pathway exists but never used in Hungary; clinical trial infrastructure is well-developed with EU alignment, but practical enforcement of stem cell regulations is inconsistent
Read the full Hungary report →
16 Jordan JO 3.0/5 Moderate Jordan has pioneering dedicated stem cell legislation (Statute No. 10 of 2014, the first Arab world statute) and strong legitimate transplant infrastructure at KHCC, but enforcement is largely absent — academic litera... Full report
The evidence behind this score 6 cited points
- Statute No. 10 of 2014 is the first dedicated stem cell law in the Arab world, establishing the National Committee for Stem Cells and defining five permissible stem cell sources.
- Documented law-practice gap: peer-reviewed analysis in Frontiers in Genetics explicitly describes unlicensed stem cell therapy trials in private hospitals with 'organizational chaos and weakness of official control mechanisms,' with no documented enforcement actions.
- No mandatory institutional stem cell research oversight committees; no national body designated to approve research protocols.
- KHCC demonstrates legitimate transplant sector with JCI accreditation, EBMT membership, and ~200 HSCT procedures annually; University of Jordan Cell Therapy Center registers clinical trials on ClinicalTrials.gov.
- Informed consent requirements exist under Article 8 but are acknowledged as incomplete: no conflict-of-interest disclosure, no comprehension assessment, no withdrawal rights specified.
- The statute fails to distinguish between autologous and allogeneic therapies or between minimally and more-substantially-manipulated cell products, creating legal ambiguity.
Read the full Jordan report →
17 Mexico MX 3.0/5 Moderate Mexico has a foundational regulatory framework through COFEPRIS and the General Health Law with structured clinical trial oversight and some enforcement precedent, but lacks stem cell-specific legislation despite a de... Full report
The evidence behind this score 5 cited points
- Of 76 confirmed regenerative medicine clinic locations in Tijuana, only 1 matched COFEPRIS licensing records, indicating 98.7% of clinics appear unlicensed
- PROY-NOM-260-SSA1, the proposed specific standard for stem cell therapies, has been pending since 2015/2017 without approval
- Only hematopoietic stem cell transplants for blood and immune disorders are officially authorized by COFEPRIS; all other stem cell applications remain unapproved
- COFEPRIS explicitly lacks sufficient financial and human resources to effectively police stem cell clinics despite having statutory authority
- January 2026 General Health Law reform added formal stem cell definitions and prohibits commercial trade, while COFEPRIS develops advanced therapy framework modeled on Spain's system
Read the full Mexico report →
18 Thailand TH 2.5/5 Moderate Thailand's stem cell regulatory framework is fragmented and evolving but undermined by critical loopholes. While the country has established clinical trial infrastructure, increasing enforcement (400+ annual prosecuti... Full report
The evidence behind this score 5 cited points
- No dedicated stem cell law; regulation fragmented across Drug Act B.E. 2510 (1967), Medical Council Regulation B.E. 2552 (2009), and Medical Device Act administered by three separate MOPH branches
- Only two stem cell indications approved: hematopoietic stem cell transplantation for blood disorders and corneal/limbal transplantation; no novel cell therapy medicinal products formally registered
- Critical regulatory loophole: autologous stem cells classified as non-drugs, falling outside Thai FDA oversight and enabling unauthorized clinic operations
- Enforcement active and increasing: over 400 cases prosecuted annually for exaggerated claims; landmark 2025 criminal fraud conviction held physician, clinic owner, and advertising agency jointly liable
- Cell Therapy Act draft stalled since 2019 despite public hearings; Medical Council authority limited to physicians only, not business operators who drive commercial market
Read the full Thailand report →
19 India IN 2.0/5 Poor India presents a minimal or ineffective regulatory framework despite comprehensive written guidelines. The National Guidelines for Stem Cell Research 2017 lack statutory backing and binding authority, while the ICMR a... Full report
The evidence behind this score 6 cited points
- The NGSCR guidelines lack statutory backing and neither ICMR nor DBT have jurisdiction to enforce compliance or penalize violations
- Hundreds of clinics in India offer unproven stem cell therapies despite stringent written guidelines
- The two-tier oversight structure (NAC-SCRT/IC-SCR) was dissolved in March 2024, citing difficulties in implementation
- CDSCO is extremely understaffed and low in resources, limiting capacity to monitor or enforce compliance
- Only hematopoietic stem cell transplantation and limbal stem cell transplantation are legally permissible outside clinical trials; Stempeucel is a rare exception
- Courts tend to favor medical providers in malpractice cases, and foreign patients face significant barriers to legal recourse
Read the full India report →

See the full ranking, the 1–5 rubric and the reports →